Symmetry Partners LLC Cuts Stake in Insulet Co. (NASDAQ:PODD)

Symmetry Partners LLC lowered its position in shares of Insulet Co. (NASDAQ:PODD) by 7.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,682 shares of the medical instruments supplier’s stock after selling 286 shares during the quarter. Symmetry Partners LLC’s holdings in Insulet were worth $961,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in Insulet during the 4th quarter worth $36,000. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in shares of Insulet by 30.1% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,395 shares of the medical instruments supplier’s stock worth $2,192,000 after purchasing an additional 1,942 shares during the period. Fisher Asset Management LLC grew its stake in shares of Insulet by 0.9% during the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock worth $81,719,000 after purchasing an additional 3,113 shares during the period. Orion Portfolio Solutions LLC grew its stake in shares of Insulet by 86.2% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 7,826 shares of the medical instruments supplier’s stock worth $1,822,000 after purchasing an additional 3,623 shares during the period. Finally, Nomura Asset Management Co. Ltd. grew its stake in shares of Insulet by 5.7% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 153,416 shares of the medical instruments supplier’s stock worth $35,708,000 after purchasing an additional 8,301 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PODD shares. Wells Fargo & Company upped their price target on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research note on Friday, February 21st. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target on the stock. Canaccord Genuity Group upped their price target on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Raymond James reaffirmed an “outperform” rating and set a $328.00 price target (up from $294.00) on shares of Insulet in a research note on Friday, February 21st. Finally, Citigroup upped their price target on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares in the company, valued at $3,187,240. This represents a 52.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.47% of the company’s stock.

Insulet Price Performance

Insulet stock opened at $265.82 on Thursday. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $289.46. The stock has a market capitalization of $18.67 billion, a P/E ratio of 45.91, a P/E/G ratio of 3.62 and a beta of 1.29. The firm’s 50-day moving average is $272.21 and its two-hundred day moving average is $256.19. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities analysts predict that Insulet Co. will post 3.92 earnings per share for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.